Oncology Investors’ Conference in New York
Dr. Gábor Somlyai, general director and chief scientist of HYD Pharma and HYD LLC for Cancer Research and Drug Development had a lecture on 12 November at the Oncology Investors’ Conference in New York on the HYD group, on research results in deuterium depletion, as well as on the potential therapeutic applications of the procedure and the pharmaceutical development based on that.
The conference was organized with the support of the American National Foundation for Cancer Research (NFCR) on 12-13 November. Its aim was to generate connections between venture capital investors in life sciences and oncology, top managers of the pharma industry, and representatives of oncological startup companies and anticancer foundations, so they can discuss possibilities of investment into oncological research and development, and international trends of development.
NCR was founded in 1973, with the Hungarian Noble laureate Albert Szent-Györgyi as one of the founders. Aim of the foundation is to support anticancer research, to promote information of the public for prevention and early diagnosis. NCFR is committed to research efforts that can promote more efficient cancer therapy, supports cooperation of scientists, and contributes to dissemination of oncological innovations.